•  

Posts Tagged: antibiotics

BioTuesdays features Xagenic and company’s molecular diagnostic beta trials

"Closely-held Xagenic plans to conduct beta studies this year, in advance of a major chlamydia and gonorrhea clinical trial, with its rapid X1 molecular diagnostic testing system in preparation for market launches in Europe and the U.S.," Leonard Zahr wrote in a feature article on Xagenic's product development progress for BioTuesdays on April 19, 2016. Xagenic was founded by University of Toronto Professor Shana Kelley in partnership with MaRS Innovation and U of T's Innovations & Partnerships Office in 2010. The company ... Read more

Stem Cell Therapeutics, UHN and MaRS Innovation Announce Novel, Clinical-Stage, Cancer Stem Cell Program Agreement

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS), a life sciences company developing stem cell-related technologies, today announced the signing of an agreement with University Health Network (UHN), through its commercialization agent MaRS Innovation (MI), both of Toronto. The agreement provides Stem Cell Therapeutics ("SCT") with an option to an exclusive world-wide license to an innovative cancer stem cell program. This agreement produced a license for a UHN technology on April 17, 2013. (more…) Read more